The second‐generation taxane cabazitaxel has been clinically approved for the treatment of
metastatic castration‐resistant prostate cancer after docetaxel failure. Compared with the …

Cabazitaxel is a second-generation taxane with promising anti-tumor activity and is
approved for treating hormone-refractory metastatic prostate cancer previously treated with …

Abstract Cabazitaxel (CTX), a second-generation taxane, has shown more anticancer
efficacy in both docetaxel and paclitaxel-resistance cancer models according to the in vivo …

Until recently, patients with castration-resistant prostate cancer (CRPC) had limited
therapeutic options once they became refractory to docetaxel chemotherapy, and no …

BACKGROUND: Although the taxanes paclitaxel and docetaxel are among the most active
agents for the treatment of a wide range of cancers, tumours often develop resistance to …

Recent advances in the management of prostate cancer have shown considerable
development with time and many novel therapeutic agents have been approved over the …

The taxanes are recognized as a major class of chemotherapeutic agents; however,
mechanisms of innate and acquired resistance can limit their usefulness. Cabazitaxel, a …

Taxane-based chemotherapeutics are clinically available as frontline treatment regimens for
cervical cancer. However, drug resistance and life-threatening toxicity impair the clinical …

Cabazitaxel is a new taxane characterized by convenient administration, a favorable
pharmacokinetic and safety profile and a decreased propensity for P-glycoprotein (Pgp) …

The development of drug resistance is a major obstacle to effective cancer therapy. Several
agents are in clinical development with the goal of overcoming resistance. Among them is …